

## AUTHOR INDEX

- Admiral, J., S1:7-11  
 Advani, R.H., 270-281  
 Afek, A., S1:12-16  
 Ahmed, S., S1:22-28  
 Anderson, K.C., S3:1-2, 3-8, 14-20  
 Angelopoulou, M.K., 104-114, 178-197  
 Appelbaum, F.R., 401-410  
 Arcasoy, M.O., 328-339  
 Arepally, G., S1:12-16  
 Aster, R.H., S1:2-6
- Bakhos, M., S1:22-28  
 Barbui, T., S2:14-18  
 Bartlett, N.L., 164-170  
 Bennett, C. L., S2:26-29  
 Berenson, J.R., S3:9-13  
 Berger, F., 198-208  
 Bergsagel, P.L., S3:9-13  
 Berliner, N., 325-327  
 Bick, R., S1:42-56  
 Blakeman, B., S1:37-41  
 Blank, M., S1: 12-16  
 Boussiotis, V.A., 209-216  
 Brown, K.E., 352-360  
 Brugger, W., 233-241
- Cadafalch, J., 75-87  
 Callas, D., S1:42-56  
 Campo, E., 115-127  
 Carmel, R., 1-2, 88-100  
 Catovsky, D., 148-154  
 Chan, W.C., 242-252  
 Cines, D.B., S1:12-16  
 Cohen, M., S1:33-36  
 Coiffier, B., 198-208  
 Corr, M., S3:38-42
- Delabesse, E., 373-389  
 Diehl, V., 282-289  
 Donaldson, S.S., 313-323  
 Donovan, K., S3:30-33  
 Drachenberg, M.R., 128-138
- Eldor, A., S1:12-16  
 Emmens, R., 253-259  
 Engert, A., 282-289
- Fareed, J., S1:42-56  
 Felman, P., 198-208  
 Finazzi, G., S2:14-18  
 Freedman, A.S., 209-216
- Gale, R.E., 361-372  
 Gallagher, P.G., 328-339
- Gilbert, H.S., S2:19-22  
 Gillis, S., 155-163  
 Goldstone, A.H., 303-312  
 Golub, R.M., S2:26-29  
 Green, R., 47-64
- Hakimian, D., 155-163  
 Hamblin, T.J., S3:3-8, 30-33  
 Harris, N.L., 220-232  
 Hart, D.N.J., S3:21-25  
 Hernandez, A.M., 128-138  
 Hoppensteadt, D.A., S1:42-56  
 Horning, S.J., 270-281  
 Hudson, M.M., 313-323  
 Hummel, M., 233-241
- Isaacson, P.G., 139-147
- Jaffe, E.S., 115-127, 217-219  
 Jarrett, R.F., 260-269  
 Jeske, W.P., S1:22-28
- Kelton, J. G., S1:17-21  
 Kittas, C., 104-114  
 Kontopidou, F.N., 178-197  
 Kotsi, P., 171-177  
 Kwak, L.W., S3:34-37
- Laurence, A.D.J., 303-312  
 Levine, A.M., 128-138  
 Lewis, B.E., S1:22-28, 29-32, 42-56  
 Liebowitz, D., S3:26-29  
 Lillicrap, D., 340-351  
 Link, C.J., S3:38-42  
 Lokhorst, H.M., S3:26-29  
 Longo, D.L., 164-170  
 Lust, J.A., S3:14-20
- Macintyre, E.A., 373-389  
 MacKenzie, J., 260-269  
 Maloney, D.G., S3:30-33  
 Massaia, M., S3:34-37  
 Matutes, E., 148-154  
 Mauch, P.M., 290-302  
 Miller, J.W., 47-64  
 Munshi, N., S3:9-13  
 Murphy, S., S2:9-13
- Nadler, L.M., 209-216  
 Nathwani, B.N., 128-138  
 Ng, A., 290-302
- Panayiotidis, P., 171-177  
 Pangalis, G.A., 101-103, 104-114, 178-197
- Peterson, L.C., 155-163  
 Polliack, A., 155-163  
 Poppema, S., 253-259  
 Potters, M., 253-259
- Raffeld, M., 115-127  
 Remacha, A.F., 75-87  
 Robinson, J.A., S1:29-32  
 Rosenblatt, D.S., 19-34  
 Rothenberg, S.P., 65-74
- Salles, G., 198-208  
 Schultze, J.L., S3:21-25  
 Sheibani, K., 128-138  
 Shoenfeld, Y., S1:12-16  
 Siakantaris, M.P., 104-114  
 Silverstein, M.N., S2:23-25  
 Stein, H., 233-241  
 Stevenson, F.K., S3:1-2, 38-42  
 Stewart, A.K., S3:21-25
- Tallman, M.S., 155-163  
 Tavor, S., S1:12-16  
 Tefferi, A., S2:1-2, 3-8, 23-25  
 Thieblemont, C., 198-208  
 Thielemans, K., S3:34-37  
 Traynor, A., S3:3-8, 38-42
- Van den Berg, A., 253-259  
 Vassilakopoulos, T.P., 104-114  
 Visser, L., 253-259
- Walenga, J.M., S1:1-6, 22-28, 42-56  
 Weinberg, P.O., S2:26-29  
 Whitehead, V. M., 19-34  
 Wickramasinghe, S.N., 3-18  
 Willman, C.L., 390-400  
 Wolf, J., 282-289  
 Wood, J.J., S1:22-28
- Yu, H., S3:38-42
- Ziporen, L., S1:12-16  
 Zittoun, J., 35-46  
 Zittoun, R., 35-46

*Subject and author entries are listed for all 1999 supplements paginated prior to compilation of this index. Other 1999 supplements will be included in future cumulative indices.*

## SUBJECT INDEX

- ABCM chemotherapy, for multiple myeloma, S3:5  
 $\alpha 4/\beta 7$  receptor, in MALT lymphoma, 142  
 Acquired disorders. *See also specific acquired disorders*  
   diagnosis/follow-up of, 325-326  
 ACRS (amplification-created restriction site), 334  
 Acute lymphoblastic leukemia (ALL)  
   B-cell, chromosomal abnormalities in, 381, 382  
   cytogenetically-guided treatment, 407-408  
   cytogenetic risk groups, 406-407  
   follow-up, molecular, 384  
   molecular diagnosis, 383-384  
   prognosis, 406-407  
   T-cell, chromosomal abnormalities in, 381  
   treatment monitoring, cytogenetic, 408  
 Acute myeloid leukemia (AML)  
   CFB $\beta$  and, 390-392  
   chromatin acetylation, 393-394  
   CREB-binding protein translocations, 393  
   in elderly, cytogenetics of, 394-396  
   from HDT and ABMT, 212  
   incidence, 390  
   MLL gene 11q23 translocations, 393  
   prognosis, 401-403  
   RAR- $\alpha$  translocations, 392-393  
   residual disease monitoring, molecular, 396-398  
   secondary, myelodysplastic syndrome and, 394-396  
   survival rates, 402, 404  
   transcriptional regression, 393-394  
   XCIP analysis, 368-370  
   in younger patients, cytogenetics of, 390-394  
 Acute promyelocytic leukemia (APL)  
   cytogenetically-guided treatment, 403-405  
   minimal residual disease, molecular monitoring of, 396  
   RAR- $\alpha$  translocations, 392-393  
 AdCAIL-2, for multiple myeloma, S3:24  
 Adenosyl-Cbl (deoxyadenosine cobalamin), 66, 67  
 Adenosylcobalamin deficiency, 26  
 Adhesion molecules. *See also specific adhesion molecules*  
   in B-chronic lymphoproliferative disorders, 180-193. *See also specific B-chronic lymphoproliferative disorders*  
   classification, 178, 179  
   detection methods, 180  
   functions, 178-179  
   in multiple myeloma, S3:14, 15  
 Adoptive T-cell therapy, S3:26-29  
 Agnogenic myeloid metaplasia (AMM)  
   diagnosis, S2:1  
   pathogenetic mechanisms, S2:4-5  
 Agrylin. *See* Anagrelide  
 AIHA (autoimmune hemolytic anemia), in B-CLL, 107  
 ALCL (anaplastic large-cell lymphoma), 228-229  
 ALCL-HL (Hodgkin-like anaplastic large-cell lymphoma), 228, 229  
 Alkylating agents. *See also specific alkylating agents*  
   for essential thrombocythemia, S2:20-21  
   for polycythemia vera, S2:20-21  
 Alkylating agents. *See also specific alkylating agents (Continued)*  
   for splenic lymphoma with villous lymphocytes, 153  
 ALL. *See* Acute lymphoblastic leukemia  
 Allogeneic bone marrow transplantation  
   for acute myelocytic leukemia, 403-404  
   donor leukocyte infusions after, S3:26-27  
   for low-grade lymphoma, 211-212  
 Allogeneic stem-cell transplantation  
   improving outcome for multiple myeloma, S3:5  
   v autologous multiple myeloma, S3:4-5  
 All-trans-retinoid acid (ATRA), for acute promyelocytic leukemia, 392-393, 403  
 AML. *See* Acute myeloid leukemia  
 AMM. *See* Agnogenic myeloid metaplasia  
 Amplification-created restriction site (ACRS), 334  
 Amplification refractory mutation system (ARMS), 333-334  
 Amplification strategies. *See also* PCR-based techniques  
   for viral infection diagnosis, 356-357  
 Anagrelide (Agrylin)  
   clinical studies, S2:24  
   cost-effectiveness, S2:26-28  
   for essential thrombocythemia, S2:16, 23-25  
   pharmacology, S2:23-24  
   therapeutic role, current, S2:24-25  
   toxicity, S2:24  
 Anaplastic large-cell lymphoma (ALCL), 228-229  
 Ancrod, for heparin-induced thrombocytopenia, S1:19  
 Angiogenesis, in multiple myeloma, S3:12  
 Animal models, cobalamin deficiency in, 8  
 Antibiotic therapy, for gastric MALT lymphoma, 143-144  
 Antibody assays, for HIT, S1:8-9  
 Antibody receptors, in HIT pathogenesis, S1:9-10  
 Anti-CD38 antibody therapy, for multiple myeloma, S3:30-31  
 Anticonvulsants, neural tube defect and, 14  
 Antigens, in HIT pathogenesis, S1:8-10  
 Anti-H-PF4 antibodies, induction of, S1:13-15  
 Antiplatelet agents, for heparin-induced thrombocytopenia, S1:20  
 Antithrombin drugs  
   clinical applications, S1:46-50  
   cost considerations, S1:51  
   development, unresolved issues in, S1:50, 53  
   future trends, S1:51-53  
   pharmacologic development, S1:42-46  
   thrombin inhibitors. *See* Thrombin inhibitors  
   with thrombolytic therapy, S1:48  
 APL. *See* Acute promyelocytic leukemia  
 Aplastic anemia, XCIP analysis, 368  
 Aptamers, S1:46  
 Argatroban (Novastan)  
   for acute ischemic syndromes, S1:47-48  
   as adjunctive anticoagulant, S1:48  
   development, S1:44  
   for heparin-induced thrombocytopenia, S1:20  
 ARMS (amplification refractory mutation system), 333-334  
 Aspirin  
   for essential thrombocythemia, S2:15-16, 21-22

*Subject and author entries are listed for all 1999 supplements paginated prior to compilation of this index. Other 1999 supplements will be included in future cumulative indices.*

- Aspirin (*Continued*)  
 for polycythemia vera, S2:21-22
- ATRA (all-*trans*-retinoid acid), for acute promyelocytic leukemia, 392-393, 403
- Autoantibodies, drug-induced, S1:3
- Autoimmune hemolytic anemia (AIHA), in B-CLL, 107
- Autologous bone marrow transplantation  
 for acute myelocytic leukemia, 403-404  
 for low-grade lymphoma, 210-211
- BALT (bronchus-associated lymphoid tissue), 145
- B-cell chronic lymphocytic leukemia (B-CLL)  
 adhesion molecules in, 181-186  
 bone marrow features, 106  
 bone marrow transplantation for, 212-214  
 chromosomal deletions, 171-172  
 clinical features, 104-105  
 cytogenetic/molecular features, 108  
 differential diagnosis, 109-110  
 disease transformation features, 108-109  
 disordered immunity in, 107-108  
 hematologic features, 105-106  
 immunophenotype, 107  
 lymph node biopsy features, 106-107  
 prognosis, 108  
 translocations, 172  
 trisomy 12 in, 172
- B cells  
 clonality, Southern blot analysis of, 377-378  
 development, immunoglobulin rearrangements in, 373-377  
 disorders of. *See specific B-cell disorders*  
 EBV transformations, 261  
 function, in Hodgkin's lymphoma, 256-257  
 malignant, CD40-activated, S3:23-24  
 normal development, HRS cell mapping onto, 237-239
- B-chronic lymphoproliferative disorders (B-CLD). *See also specific B-chronic lymphoproliferative disorders*  
 adhesion molecules in, 180-193  
 soluble CD44 and CD54 in, 190, 192  
 variant CD44 isoforms in, 190
- Bcl-2 oncogene  
 protein overexpression, in follicular lymphomas, 174  
 rearrangement, in classical Hodgkin's lymphoma, 226
- bcr/abl oncogene, in chronic myelogenous leukemia, S2:5-6
- Bisphosphonates, for multiple myeloma, S:5-6
- Blacks, pernicious anemia in, 94-95
- Bleeding complications, in essential thrombocythemia, S2:14-15
- Blood transfusions, viral infections from, 354
- B lymphocytes. *See B cells*
- Bone marrow  
 donation, viral infections from, 354  
 fibrosis, in agnogenic myeloid metaplasia, S2:4-5  
 in folate or cobalamin deficiency, 36-37  
 in hairy-cell leukemia, 155-156  
 in mantle-cell lymphoma, 118  
 in splenic lymphoma with villous lymphocytes, 150
- Bone marrow transplantation (BMT)  
 allogeneic. *See Allogeneic bone marrow transplantation*  
 autologous. *See Autologous bone marrow transplantation*  
 in B-CLL, 212-214
- donor leukocyte infusions after, S3:26-27  
 in low-grade lymphoma, 209-210  
 viral infections from, 354-355
- Bronchus-associated lymphoid tissue (BALT), 145
- Burkitt's lymphoma, chromosomal abnormalities in, 381-382
- Busulfan, for essential thrombocythemia, S2:20-21
- Cancer and Leukemia Group B trial (CALBG trial), 403, 404, 405
- Cancer risk, folate deficiency and, 15, 58
- CblA disease, 26
- CblB disease, 26
- CblE disease, 28
- CblG disease, 28
- 2CdA (2-chlorodeoxyadenosine), for hairy-cell leukemia, 158-159
- CDK inhibitors, in mantle-cell lymphoma pathogenesis, 122
- CD40 ligand, activation of multiple myeloma cells, S3:14
- CD4<sup>+</sup> T cells, in Hodgkin's lymphoma, 256
- Cereal-grain fortification, with folic acid. *See Folate, food fortification*
- Chemokine expression, in Reed-Sternberg cells, 255-258
- Chemokine receptor expression, in Reed-Sternberg cells, 255-258
- Chemotherapy. *See also specific chemotherapeutic agents*  
 combination, for multiple myeloma, S3:3-4, S3:5  
 for hairy-cell leukemia, 157  
 high-dose  
     with bone marrow transplantation, 209-210  
     v conventional for multiple myeloma, S3:4  
 for multiple myeloma, S3:3-4  
 for mycosis fungoides, 167-168  
 for small lymphocytic lymphoma, 203-205
- Children  
 essential thrombocythemia in, S2:16-17  
 nutritional cobalamin deficiency in, 20-23
- 2-Chlorodeoxyadenosine (2-CdA), for hairy-cell leukemia, 158-159
- CHOP, for mantle-cell lymphoma, 205
- Chorionic villus sampling (CVS), 328-329
- Chronic B-lymphoid leukemias, molecular cytogenetics, 385-386
- Chronic lymphocytic leukemia (CLL)  
 B-cell. *See B-cell chronic lymphocytic leukemia*  
 T-cell, 164-165. *See also T-cell prolymphocytic leukemia*
- Chronic myeloid leukemia (CML)  
 pathogenetic mechanisms in, S2:5-6  
 XCIP analysis, 367
- Chronic myeloproliferative disorders (CMPDs)  
 agnogenic myeloid metaplasia. *See Chronic myeloid leukemia*  
 characteristics, S2:1  
 essential thrombocythemia. *See Essential thrombocythemia*  
 myelodysplastic syndrome. *See Myelodysplastic syndrome*  
 pathogenetic mechanisms, S2:3-6  
 polycythemia vera. *See Polycythemia vera*  
 types of, S2:1  
 XCIP analysis, 367-368
- CLL. *See Chronic lymphocytic leukemia*
- Clonality analysis  
 assays for, 361, 362

Clonality analysis (*Continued*)

- DNA-based, 363-364
- in lymphocyte-predominant Hodgkin's lymphoma, 245-247
- non-Hodgkin's lymphomas, 384-385
- RNA-based, 364-365
- Southern blot, 377-378
- X-chromosome inactivation pattern for, 361-364

CML. *See* Chronic myeloid leukemiaCMPDs. *See* Chronic myeloproliferative disorders; Myelodysplastic syndromeCobalamin (B<sub>12</sub>)

- absorption, 23-24
- assay methods, 38-39
- biochemistry, 4-5
- deficiency. *See* Cobalamin deficiency
- dietary requirements, 19
- ethnic variation, 88, 89-91
- metabolic alterations, in HIV-infected patients, 77-78
- serum levels, 10
- survival of HIV-positive patients and, 76-77
- synthesis, 19

## Cobalamin deficiency

- in animals, 8
- in children, 20-23
- clinical features, 12-14, 96
- clinical testing strategies, 41-43
- cytokinetic abnormalities, 3-4
- deoxyuridine suppression in, 5-6
- developmental stages of, 11-12
- diagnosis, 20, 35-36
- diagnostic tests for, 10-11, 36-41
- disorders. *See* Megaloblastic anemia; Pernicious anemia
- ethnic variations in, 96-97
- hereditary, 23-28, 96
- in HIV-infected patients
  - dietary intake and, 76
  - epidemiology of, 75-76
  - evaluation of deficits in, 83-85
  - hematologic changes, B<sub>12</sub>-related, 77-81
  - neurologic changes, B<sub>12</sub>-related, 81-83
  - survival prediction in, 76-77
- from inborn errors
  - in absorption, 23-24
  - in transport, 23-24
  - in utilization, 25-28
- ineffective hemopoiesis in, 4
- laboratory abnormalities in, 12-13
- from malabsorption
  - diagnosis of, 40-41
  - from food, 13-14
  - in HIV-infected patients, 80-81
- megaloblastic changes in, 7-8
- methionine synthase impairment in, 6-7
- mild, management of, 15
- neuropathy, 13, 14
  - biochemical basis, 9-10
  - hematologic abnormalities and, 14
  - pathophysiology, 68
- neuropsychiatric disorders, 67-68
- nutritional, 20-23
- progression, 1-2

Cobalamin deficiency (*Continued*)

- testing strategies
  - in absence of hematologic abnormalities, 42-43
  - in presence of hematologic abnormalities, 41-42

Cobalophilin. *See* Transcobalamin I

## Coronary artery disease, LMW heparins in, S1:34-36

## CREB-binding protein translocations, in acute myeloid leukemia, 393

## CVS#995, S1:43-44

## Cyclin D1

- in mantle-cell lymphoma, 119, 121-122, 173
- molecular analysis, 385

## Danaparoid, for heparin-induced thrombocytopenia, S1:19

## 2'-DCF (2'-deoxycoformycin), for hairy-cell leukemia, 157-158, 159

## Deep vein thrombosis, LMW heparins in, S1:35

## Dehydroepiandrosterone (DHEA), for MGUS, S3:18-19

## Deletions, in B-CLL, 171-172, 173

## Dendritic cells

- differentiation pathway, S3:21, 22
- harvesting, S3:22
- in multiple myeloma, S3:10
- retrovirally transduced, for multiple myeloma, S3:39-40
- TAA-specific T-lymphocyte responses and, S3:21-22

## Deoxyadenosine cobalamin (adenosyl-Cbl), 66, 67

## 2'-Deoxycoformycin (2'-DCF), for hairy-cell leukemia, 157-158, 159

## Deoxyuridine suppression test

- in B<sub>12</sub> (cobalamin) deficiency
  - diagnostic applications, 5-6, 37-38
  - in HIV-infected patients, 84
  - in folate deficiency, 5-6, 37-38

## Depression, folate deficiency and, 55-56

## Developmental abnormalities, folate deficiency and, 54

## DHEA (dehydroepiandrosterone), for MGUS, S3:18-19

## Dietary Intervention Study in Children, 22

## Diffuse large-cell lymphoma (DLCL), lymphocyte-predominant Hodgkin's lymphoma and, 247-248

## Direct hybridization, for viral infection diagnosis, 356

## DLCL (diffuse large-cell lymphoma), lymphocyte-predominant Hodgkin's lymphoma and, 247-248

## DNA

- damage, in B<sub>12</sub> and folate deficiency, 8-9
- synthesis
  - arrest, in B<sub>12</sub> and cobalamin deficiency, 3-4
  - in megaloblasts, 7

## DNA analysis

- in diagnosis/follow-up of acquired disease, 326
- fetal sampling methods, 328-329
- genomic
  - β-globin gene defects, 331-332
  - α-thalassemia, 330
- PCR-amplified, β-globin gene defects, 332-334
- of XCIPs, 363-364

## DNA chips, 359

## DNA vaccines

- gene gun-mediated tumor cell, S3:40-41
- HAV/EBV amplicon vector, S3:40
- pathfinder, S3:38-39
- retrovirally transduced dendritic, S3:39-40

DNA vaccines (*Continued*)

- DNCB skin sensitivity, folate deficiency and, 57
- Dot-blot method,  $\beta$ -globin gene defect detection, 332-333
- Drug-induced immune thrombocytopenia (DITP). *See also*
  - Heparin-induced immune thrombocytopenia with thrombosis syndrome
  - GP1Ib/IIIa inhibitor-associated, S1:5
  - mechanisms of, S1:2-5
- dUMP, conversion impairment, 5-6

EBV. *See* Epstein-Barr virus

EBV nuclear antigen, 260, 261

Ecarin clotting time (ECT), S1:50

## ELISA

- Anti-H-PF4 antibody, S1:13-15
- heparin-PF4, S1:18
- for HIT/HITTS evaluation, S1:23, 24-28
- for H-PF4 antibodies, S1:8-9

Enterocytes, defective cobalamin transport by, 23-24

EPO (erythropoietin), in polycythemia vera, S2:3

## Epstein-Barr virus (EBV)

- B-cell transformations, 261
- hematologic consequences of, 353
- Hodgkin's lymphoma and, 260
- infections, forms of, 260-261
- latent genes, 261
- in lymphocyte-predominant Hodgkin's lymphoma, 245
- nuclear antigen, 260, 261
- in Reed-Sternberg cells, 253
- as vector for DNA vaccine, S3:40

Erythrocyte enzymopathies, genetic diagnosis of, 334-335

Erythropoietin (EPO), in polycythemia vera, S2:3

Erythropoietin receptor, in polycythemia vera, S2:3-4

## Essential thrombocythemia (ET)

- in children, S2:16-17
- classification, S2:14
- clinical features, S2:10
- complications
  - bleeding, S2:14-15
  - thrombotic, S2:14-15, 23
- diagnosis, S2:1, S2:9-10
- differential diagnosis, S2:9-10
- mortality/morbidity, S2:11-12
- natural course, S2:10-11
- pathogenetic mechanisms, S2:4
- during pregnancy, S2:17
- symptoms, S2:9, S2:23
- treatment
  - alkylating agents for, S2:20-21
  - anagrelide for. *See* Anagrelide
  - aspirin for, S2:15-16, S2:21-22
  - historical perspective, S2:19-22
  - hydroxyurea for, S2:15, 20
  - interferons for, S2:16, 21

## Ethnicity

- cobalamin deficiency and, 96-97
- cobalamin serum levels and, 88, 89-91
- disease expression and, 88-89
- food-cobalamin malabsorption and, 96
- homocysteine and, 91-92
- pernicious anemia and, 94-95

Ethnicity (*Continued*)

transcobalamins and, 92-93

Extranodal lymphomas, primary. *See* MALT lymphoma

Fibroblast growth factor receptor 3 gene (FGFR3), in multiple myeloma, S3:11-12

FISH analysis, of lymphoid malignancies, 379-380

## Fludarabine

- for marginal-zone lymphoma, 205-206
- for small lymphocytic lymphoma, 205
- for splenic lymphoma with villous lymphocytes, 153

## Folate

- absorption, congenital disorders of, 55
- assay methods, 38-39
- biochemistry, 4-5
- congenital metabolic disorders, 30-32, 55
- deficiency
  - acquired, 28-29
  - biochemical tests for, 10-11
  - cancer and, 15
  - cardiovascular complications, 47-56
  - in children, 19-20
  - clinical features, 12-14
  - coronary vascular risk and, 53-54
  - cytokinetic abnormalities, 3-4
  - deoxyuridine suppression in, 5-6
  - developmental abnormalities and, 48, 54
  - developmental stages of, 11-12
  - diagnosis, 20, 35-41, 47, 59-61
  - diagnostic testing strategies, 36-43
  - epithelial complications, 48
  - gastrointestinal dysfunction and, 56
  - hematologic variants, 58-59
  - hereditary, 30-32
  - hyperhomocysteinemia and, 47-49, 51-53
  - immunological deficits and, 56-58
  - ineffective hemopoiesis in, 4
  - laboratory abnormalities, 12-13, 60-61
  - maternal, fetal effects of, 29
  - metabolic complications, 48
  - mild, management of, 15
  - neoplastic/preneoplastic complications, 48, 58
  - neural tube defects and, 14, 69-70
  - neurological complications, 48, 54-56
  - sequelae, 1
- diagnostic testing strategies
  - in absence of hematologic abnormalities, 42-43
  - in presence of hematologic abnormalities, 41-42
- dietary requirements, 19
- drug interactions, 52
- food fortification
  - cardiovascular risk and, 53-54
  - concerns on, 65-66
  - opposition to, 67-68, 70-72
  - support for, 65, 69-70
- functions, 4
- malabsorption, diagnosis of, 41
- metabolic pathways, 66-67
- for pernicious anemia, 71-72
- recommended daily allowance, 69
- red blood cell levels, 10, 29

- Folate (*Continued*)  
 reduced form, 4-5  
 serum levels, 10  
 transport, inborn errors of, 30-32  
 vascular disease and, 15
- Folic acid. *See* Folate
- Follicular lymphoma  
 adhesion molecules in, 188, 190, 191  
 classification, 209  
 development from germinal center B-cell, 237-239  
 genetics, 173-174, 385  
 malignant monocytic B cells in, 132  
 molecular analysis, 385  
 small cleaved-cell lymphoma, differential diagnosis of, 109
- Food  
 cobalamin malabsorption from, ethnic variations in, 96  
 folic acid fortification. *See* Folate, food fortification
- Food cobalamin absorption tests, 13-14
- Formate starvation hypothesis, 6-7
- Gastrointestinal dysfunction  
 folate deficiency and, 56  
 in mantle-cell lymphoma, 118-119
- Gene gun-mediated tumor cell DNA vaccines, S3:40-41
- Genetic immunotherapy, for multiple myeloma, S3:24
- Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO), S1:47
- Globin gene defects  
 $\alpha$ -, genetic diagnosis of, 330  
 $\beta$ -, genetic diagnosis of, 331-334
- Glucose-6-phosphate dehydrogenase (G6PD), genetic diagnosis of, 334
- Glutamate formiminotransferase deficiency, 31-32
- G6PD (glucose-6-phosphate dehydrogenase), genetic diagnosis of, 334
- GP1Ib/IIIa inhibitor -induced immune thrombocytopenia, S1:5
- Graft-versus-host disease (GVHD), GVM and, S3:17
- Graft-versus-myeloma effect (GVM), S3:5, 17
- GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries), S1:47
- GVHD (graft-versus host disease), GVM and, S3:17
- GVM (graft-versus-myeloma effect), S3:5, 17
- Hairy-cell leukemia (HCL)  
 adhesion molecules in, 181, 185, 186  
 clinical findings, 155  
 cytochemical findings, 156  
 differential diagnosis, 109, 148, 150, 156  
 future treatment directions, 160  
 immunophenotypic findings, 156  
 minimal residual disease, 160  
 morphologic features, 155-156  
 prognosis, 159  
 relapse after purine analog, 160  
 second malignancy risk after, 160  
 treatment, 156-159
- Hairy-cell leukemia-variant (HCL-v), 109
- Hapten formation, in DITP, S1:2
- Haptocorrin. *See* Transcobalamin I  
 deficiency of, 24
- HAV/EBV amplicon vector DNA vaccines, S3:40
- Hb-Bart's hydrops fetalis syndrome,  $\alpha$ -globin gene defect in, 330
- HCAM (homing-associated cell adhesion molecule), 179
- HCL. *See* Hairy-cell leukemia
- HCL-v (hairy-cell leukemia-variant), 109
- HDM chemotherapy, for multiple myeloma, S3:5
- Helicobacter pylori*, gastric lymphomas and, 142-144
- Hemoglobin, in cobalamin deficiency, 12-13
- Hemoglobinopathies. *See also specific hemoglobinopathies*  
 with  $\alpha$ -globin gene defects, 329-331  
 with  $\beta$ -globin gene defects, 331-334  
 incidence, 329
- Hemophagocytic syndrome (HS), 353
- Hemopoiesis  
 arrest, in B<sub>12</sub> and folate deficiency, 3-4  
 ineffective, in B<sub>12</sub> and folate deficiency, 4
- Heparin  
 discontinuation, in HIT, S1:18-19  
 low-molecular weight. *See* LMW heparins  
 unfractionated, S1:33, 34, 35
- Heparin-induced immune thrombocytopenia with thrombosis syndrome (HITS)  
 development, S1:17, 22  
 laboratory tests, multicenter clinical trial for, S1:22-28  
 medico-legal aspects, S1:40  
 model, S1:4-5  
 sequelae, S1:37
- Heparin-induced platelet activation (HIPA)-associated events  
 clinical presentation/management, S1:37-38  
 medical-legal aspects, S1:40  
 in surgical patients, identification/management of, S1:38-40
- Heparin-induced thrombocytopenia (HIT)  
 associated clinical syndromes, S1:38  
 clinical features, S1:7-8, 17, 22, 29  
 complications, S1:29  
 "iceberg model," S1:18  
 incidence, S1:37  
 laboratory tests  
 multicenter clinical trial for, S1:22-28  
 role in diagnosis, S1:17-18, 22, 29  
 medico-legal aspects, S1:40  
 mouse model, S1:12-16  
 pathogenesis, antigens in, S1:8-10  
 treatment, S1:10-11, 18-20, 29  
 antithrombin agents for, S1:48-49  
 plasmapheresis for, S1:29-31  
 type I, S1:33-34  
 type II, S1:34
- Hepatitis C virus, marginal-zone B-cell lymphoma and, 134
- Hereditary folate malabsorption, 30
- HERO (Hirulog Early Reperfusion trial), S1:47
- Herpes simplex virus, as DNA vaccine vector, S3:40
- Herpes virus infections, hematologic consequences of, 353
- HHV-8. *See* Human herpesvirus-8
- Hirudin, side-directed, development of, S1:43, 44
- Hirulog Early Reperfusion trial (HERO), S1:47
- Histiocyte-/T-cell-rich B-cell lymphoma (H/TCRBCL), lymphocyte-predominant Hodgkin's lymphoma and, 248-249
- Histone deacetylase complex (HDAC), in transcriptional regression, 393-394
- HIT. *See* Heparin-induced thrombocytopenia



- HITT. *See* Heparin-induced immune thrombocytopenia with thrombosis syndrome (HITS)
- HIV infection  
cobalamin deficiency in  
epidemiology, 75-76  
evaluation of, 83-85  
dietary intake and, 76  
gastrointestinal changes, B<sub>12</sub> metabolism and, 78-81  
hematologic changes, B<sub>12</sub> metabolism and, 77-78  
neurologic changes, B<sub>12</sub> metabolism and, 81-83  
survival prediction, B<sub>12</sub> levels and, 76-77
- HLA, S3:23
- Hodgkin-like anaplastic large-cell lymphoma (ALCL-HL), 228, 229
- Hodgkin's lymphoma  
classical  
cellular origin, 233-234  
clinical features, 218  
cytogenetics, 226  
definition, 224  
development from germinal center B-cell, 237-239  
generalized immunodeficiency in, 256-258  
histologic variants, 224-225, 233  
immune reactions in, 253-258  
immunophenotype, 225-226, 234-235  
lymphocyte-depleted, 225  
lymphocyte-rich, 226-227  
mixed cellularity, 225  
molecular studies, 235-237  
nodular sclerosis, 224-225  
treatment, 218  
tumor necrosis factor and, 254  
classification, 217, 221-222, 223  
definition, 220-222  
differential diagnosis, 227-229  
epidemiologic features, 218  
historical background, 217  
lymphocyte-predominant. *See* Lymphocyte-predominant Hodgkin's lymphoma  
terminology, 217
- Hodgkin's Reed and Sternberg cells (HRS cells). *See* Reed-Sternberg cells
- Homing-associated cell adhesion molecule (HCAM), 179
- Homocysteine  
cobalamin (B<sub>12</sub>) status and, 10-11  
elevated levels. *See* Hyperhomocysteinemia  
ethnicity and, 91-92  
folate and, 10-11, 47-49, 70, 47-49  
vascular disease and, 15
- HRS cells. *See* Reed-Sternberg cells
- HS (hemophagocytic syndrome), 353
- H/TCRBCL (histiocyte/T-cell-rich B-cell lymphoma), lymphocyte-predominant Hodgkin's lymphoma and, 248-249
- Human herpesvirus-8 (HHV-8)  
in Kaposi's sarcoma, S3:1, 9  
multiple myeloma and, S3:1, 9-10
- HUMARA assay, 363-364
- Hydroxyurea  
for essential thrombocythemia, S2:15, 20  
for polycythemia vera, S2:19-20
- Hypergammaglobulinemia, in B-CLL, 107
- Hyperhomocysteinemia  
cardiovascular complications, folate deficiency and, 51-53  
mechanism of cardiovascular complications in, 50-51  
methylene tetrahydrofolate reductase deficiency and, 49-50
- Hyperreactive malarial splenomegaly, v SLVL, 152
- Idiotypic vaccination, for multiple myeloma, S3:34-37
- IgG antibodies, in HIT pathogenesis, S1:8
- Ig gene rearrangements, Hodgkin Reed and Sternberg cells, 236-237
- Ig/TCR receptors  
allelic exclusion, 375-376  
diversity, from Ig rearrangements, 375  
editing of, 376  
gene characteristics, 373, 374  
illegitimate rearrangement, 376-377  
light-chain locus, 376  
V-(D)-J rearrangements, 373-375
- Ig/TCR V-(D)-J gene rearrangements, PCR detection of, 378-379
- Imerslund-Gräsbeck syndrome, 23-24, 96
- Immune complex hypothesis, S1:3-4
- Immunoglobulin, heavy-chain rearrangements, 373-377
- Immunological deficits, folate deficiency and, 56-58
- Immunoproliferative small intestinal disease (IP-SID), 142
- Immunosuppression  
from purine analogs, in hairy-cell leukemia, 159  
viral infection risk and, 354
- Immunotherapy, for multiple myeloma, S3:1-2
- Indolent nonfollicular lymphomas. *See also specific indolent nonfollicular lymphomas*  
classification of, 198-199  
clinical features, 200-201  
prognostic indicators, 201-203  
time to progression, 201-203, 204  
treatment, 203-207  
treatment outcome, 203-207  
types of, 198-200
- Infants  
developmental abnormalities, folate deficiency and, 54  
nutritional cobalamin deficiency in, 20-23
- Inherited disorders. *See specific inherited disorders*
- Innocent bystander hypothesis, S1:3-4
- In situ hybridization, for viral infection diagnosis, 356
- Intercellular adhesion molecules (ICAMs), characteristics, 179
- Interferons  
for essential thrombocythemia, S2:16
- IFN- $\alpha$   
for essential thrombocythemia, S2:21  
for hairy-cell leukemia, 157  
for multiple myeloma, S3:5  
for mycosis fungoides, 168  
for polycythemia vera, S2:21
- Intergroup trial, 404
- Interleukins  
IL-6  
in MGUS, S3:17  
in multiple myeloma, S3:14-15  
IL-10, Hodgkin's lymphoma immune response and, 255  
IL-1 $\beta$ , MGUS transition to MM and, S3:17-18
- International Prognostic Index (IPI), 202-203
- Intrinsic factor deficiency, 23

- IPI (International Prognostic Index), 202-203
- Ischemic syndromes, antithrombin drugs for, S1:46-48
- Jackson and Parker classification, of Hodgkin's lymphoma, 221
- Kaposi's sarcoma, human herpesvirus-8 in, S3:9
- Kaposi's sarcoma-associated herpesvirus, multiple myeloma and, S3:15-16
- Kiel Classification, 203
- Ki-67 labeling, in mantle-cell lymphoma, 119
- Lactate dehydrogenase (LDH), prognostic significance of, 201-202
- Large B-cell lymphoma
- NLPHL and, 223
  - T-cell/histiocyte-rich, 227-228
- Large granular lymphocyte leukemia (LGL)
- natural killer cell, 166-167
  - T-cell, 166
  - terminology, 165-166
- Lennert's lymphoma, 168
- Leukocyte function-associated antigen (LFA-1)
- in B-chronic lymphocytic leukemia, 181, 182-183
  - characteristics, 179
- Leukocyte infusions, donor, after allogeneic bone marrow transplant, 26-27
- LFA-1. *See* Leukocyte function-associated antigen
- LGL. *See* Large granular lymphocyte leukemia
- LMW heparins
- in acute coronary syndromes, S1:34-36
  - heparin-induced thrombocytopenia and, S1:19
  - preparations of, S1:33, 34
  - v unfractionated heparin, S1:34, 35
- Low-grade lymphoma
- allogeneic BMT for, 211-212
  - autologous BMT for, 210-211
  - histologic transformation, treatment at, 211
  - minimal residual disease in, 214
  - purging, 214
  - refractory, 211
  - resistant relapse, treatment of, 211
  - sensitive relapse, treatment of, 210-211
- LPHL. *See* Lymphocyte-predominant Hodgkin's lymphoma
- LPL/MW. *See* Lymphoplasmacytic lymphoma; Waldenström's macroglobulinemia
- Lukes and Butler classification, of Hodgkin's lymphoma, 221
- Lung, MALT lymphoma of, 145
- Lymphocyte-predominant Hodgkin's lymphoma (LPHL)
- classification, 233, 242
  - cytogenetics, 249-250
  - DLCL and, 247-248
  - EBV in, 245
  - H/TCRBCL and, 248-249
  - L&H cells in, 233, 244-247
  - nodular. *See* Nodular lymphocyte-predominant Hodgkin's lymphoma
  - nodules in, 242-244
  - PTGC and, 249
- Lymphocytic and/or histiocytic cells (L&H)
- antigen expression, 242
  - in LPHL, 233, 244-247
- Lymphocytic and/or histiocytic cells (L&H) (*Continued*)
- Lymphocytosis, in splenic lymphoma with villous lymphocytes, 148
- Lymphoid malignancies. *See also specific lymphoid malignancies*
- chromosomal abnormalities in, 379-382
- Lymphoplasmacytic lymphoma (LPL)
- adhesion molecules in, 181, 187, 188
  - bone marrow features, 106
  - classification, 198, 199
  - clinical features, 105, 200
  - cytogenetics, 108, 174-175
  - differential diagnosis, 109-110
  - disease transformation features, 108-109
  - disordered immunity in, 107-108
  - hematologic features, 105-106
  - immunophenotypic features, 107
  - lymph node biopsy, 106-107
  - prognosis, 108
- Lymphoreticular system, direct viral infections of, 352-353
- Macrocytosis, diagnostic testing strategies, 41-42
- Major translocation cluster, in mantle-cell lymphoma, 120-121
- MALT lymphoma
- acquired, 140
  - clinicopathologic features, 135, 139-140, 142, 200-201
  - concept of, 140
  - Helicobacter pylori* and, 142-144
  - High-grade gastric, 141-144
  - immunophenotype, 141
  - low-grade gastric, 140-141, 143
  - lymph node involvement, 141
  - molecular genetics, 141-141
  - of ocular adenexa, 145
  - pathology of, 140-141
  - pulmonary, 145
  - of salivary gland, 144-145
  - sites of, 140
  - treatment of, 143-144
  - treatment/outcome for, 205-206
- Mantle-cell lymphoma (MCL)
- adhesion molecules in, 181, 188, 189
  - blastic variant, 116-117, 123
  - characteristics, 199
  - classification, 115
  - clinical features, 123, 201
  - cyclin D1 in, 119, 121-122, 173
  - cytogenetics, 119-120
  - cytologic variants, 116-117
  - differential diagnosis, 109, 116, 119, 121
  - evolution of, 123
  - extranodal involvement, 118-119
  - histologic progression, 117-118
  - immunophenotype, 119
  - malignant monocytic B cells in, 132
  - mantle-zone pattern in, 116, 123
  - molecular characteristics, 120-122
  - pathological features, 115-117
  - prognosis, 123-124
  - translocations, 119-120, 121, 173
  - treatment, 123-124



- Mantle-cell lymphoma (MCL) (*Continued*)  
treatment outcome, 205
- Marginal-zone B-cell lymphoma (MZL)  
characteristics, 199-200  
classification, 128  
clinical features, 135-136, 200-201  
cytogenetics, 133-134  
differential diagnosis, 109, 134  
hepatitis C virus and, 134  
histologic transformation, 133  
immunology, 133-134  
literature review, 129  
molecular biology, 133-134  
monocytoid B cells and, 130  
in mucosal epithelium, 130  
primary nodal, morphology of, 130-133  
treatment outcome, 205-206
- MASDA (multiplex allele-specific diagnostic assay), 333
- MCHL (mixed cellularity Hodgkin's lymphoma), 225
- MCL. *See* Mantle-cell lymphoma
- MDR1. *See* Multidrug resistance 1 expression
- Mean corpuscular volume (MCV)  
in cobalamin deficiency, 12-13  
in folate and, 20  
in folate deficiency, 59
- Medical-legal aspects, of HIPA-associated events, S1:40
- Megaloblastic anemia  
B<sub>12</sub> deficiency in. *See* Cobalamin deficiency  
deoxyuridine suppression test for, 5-6  
folate deficiency. *See* Folate, deficiency  
morphologic alterations, in HIV-infected patients, 77-78
- Megaloblasts  
characteristics of, 7-8  
DNA synthesis in, 7
- Melphalan  
high-dose, for multiple myeloma, S3:1  
and prednisone, for multiple myeloma, S3:1
- MESA (myoepithelial sialadenitis), 144-145
- Metabolite assays, in folate or cobalamin deficiency, 39-40
- Methionine synthase impairment, in cobalamin deficiency, 6-7
- Methylcobalamin deficiency, 28
- Methylenetetrahydrofolate reductase (MTHFR)  
deficiency  
diagnosis of, 30-31  
hyperhomocysteinemia and, 49-50  
homocysteine elevations and, 48
- Methylfolate trap hypothesis, 6
- Methylmalonic acid (MMA)  
assay method, 39  
in B<sub>12</sub> deficiency, 67  
in cobalamin deficiency, of HIV-infected patients, 83-84  
impairment, in B<sub>12</sub> deficiency-related neuropathy, 68  
serum levels, B<sub>12</sub>/folate status and, 10-11  
urinary, in nutritional cobalamin deficiency, 21
- Methylmalonic acidurias, 25
- Methylmalonyl CoA mutase, deficiency of, 25-26
- MGUS. *See* Monoclonal gammopathy of unknown significance
- Microbiological vitamin assays, in folate or cobalamin deficiency, 38
- Microsporidia infection, in HIV-infected patients, 80
- Minimal residual disease  
in AML, molecular monitoring of, 396-398  
detection of, 326-327  
molecular diagnosis of, 382-383
- Mixed cellularity Hodgkin's lymphoma (MCHL), 225
- Mixed lineage leukemia gene (MLL gene), 11q23 translocations, 393
- MMA. *See* Methylmalonic acid
- MM-DC (myeloma cells with dendritic cells), for multiple myeloma, S3:5
- Molecular diagnosis. *See also under specific disorders*  
techniques. *See specific molecular diagnostic techniques*  
of viral infections, 356-358
- Monoclonal antibodies  
human trials, for multiple myeloma, S3:30-32  
recombinant engineered, for multiple myeloma, S3:32-33
- Monoclonal gammopathy of unknown significance (MGUS)  
therapeutic strategies for, S3:18-19  
transition to multiple myeloma, S3:1, 17-19
- Monocytoid B-cell lymphoma. *See* Marginal-zone B-cell lymphoma
- Monocytoid B cells  
benign nodal, 128-129  
malignant nodal, 129-130  
marginal-zone B cells and, 130
- Mouse model, of heparin-induced thrombocytopenia, S1:12-16
- MP chemotherapy, for multiple myeloma, S3:5
- MPDs, S2:9
- MRC trial, 404
- MTHFR. *See* Methylenetetrahydrofolate reductase
- Mucosa-associated lymphoid tissue  
components of, 139-140  
functional properties of, 140
- Multidrug resistance 1 expression (MDR1)  
in acute myeloid leukemia, 402-403  
for treatment guidance, 405
- Multiple myeloma  
antibody treatment, S3:30-33  
cell growth/survival, S3:14-16  
chemotherapy  
conventional v combination, S3:3-4  
high-dose v conventional, S3:4  
chromosomal abnormalities, 381  
human herpesvirus-8 in, S3:1, 9-10  
immunotherapy, S3:1-2  
incidence, S3:3  
Kaposi's sarcoma-associated herpesvirus in, S3:15-16  
melphalan and prednisone for, S3:1  
MGUS transition to, S3:1, 17-19  
molecular cytogenetics, 385-386  
molecular pathogenesis, S3:11-12  
molecular subtypes, S3:1  
monoclonal antibodies for. *See* Monoclonal antibodies  
natural course, S3:3, 4  
NCCN treatment guidelines, S:6-7  
new clinical treatments for, S3:16-17  
remissions, S3:3  
stem-cell transplants for, S3:1  
survival rates, S3:3  
vaccination  
DNA, S3:38-41

- Multiple myeloma (*Continued*)  
 idiopathic, S3:34-37
- Multiplex allele-specific diagnostic assay (MASDA), 333
- Mycosis fungoides, 167-168
- Myelodysplastic syndrome (MDS)  
 characteristics, S2:1  
 from HDT and ABMT, 212  
 secondary AML and, 394-396  
 XCIP analysis, 368-370
- Myelofibrosis with myeloid metaplasia, S2:1
- Myeloid differentiation pathway, S3:21, 22
- Myeloma cells with dendritic cells (MM-DC), for multiple myeloma, S3:5
- Myoepithelial sialadenitis (MESA), 144-145
- MZL. *See* Marginal-zone B-cell lymphoma
- National Comprehensive Cancer Network (NCCN), multiple myeloma treatment guidelines, S3:6-7
- Neoantigen/compound epitope formation, in DITP, S1:2-4
- Neoplastic conditions, folate deficiency and, 58
- Neural tube defect (NTD)  
 anticonvulsants and, 14  
 folate deficiency and, 69-70  
 folate supplementation for, 14
- Neurologic dysfunction  
 in B<sub>12</sub> deficiency. *See* Cobalamin deficiency, neuropathy  
 congenital of folate absorption/metabolism disorders and, 55  
 in HIV infection, B<sub>12</sub> metabolism and, 81-83
- Neuropsychiatric disorders  
 cobalamin deficiency and, 67-68  
 folate deficiency and, 54-55
- Neutrophils, in folate or cobalamin deficiency, 36
- NK-LGL leukemias, 166-167
- Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL)  
 classification, 220-221, 222  
 clinical features, 223-224  
 immunophenotype, 223  
 large B-cell lymphoma and, 223  
 morphologic features, 222  
 progressive transformation of terminal centers, 222-223
- Nodular sclerosis Hodgkin's lymphoma (NSHL)  
 clinical features, 224-225  
 grading, 224  
 morphological features, 224
- Non-Hodgkin's lymphoma  
 chromosomal abnormalities, 381  
 clonality analysis, 384-385  
 genetic abnormalities, molecular analysis of, 385  
 histologic variants. *See specific histologic variants*  
 incidence, 209  
 low-grade, adhesion molecules in, 185-186
- Non-IgG antibodies, in HIT pathogenesis, S1:9
- Novastan. *See* Argatroban
- NTD. *See* Neural tube defect
- Nucleic acid hybridization, 358
- OAF (osteoclast-activating factor), in multiple myeloma, IL-1 $\beta$  and, S3:17, 18
- OASIS (Organization to Assess Strategies for Ischemic Syndromes), S1:47
- Ocular adenexal MALT lymphoma, 145
- Oncogenes. *See also specific oncogenes*  
 rearrangements, in classical Hodgkin's lymphoma, 226
- Open-reading frames (ORFs), in multiple myeloma, S3:10
- Oral contraceptives  
 folate deficiency and, 52  
 red blood cell folate levels and, 29
- ORFs (open-reading frames), in multiple myeloma, S3:10
- Organization to Assess Strategies for Ischemic Syndromes (OASIS), S1:47
- Osteoclast-activating factor (OAF), in multiple myeloma, IL-1 $\beta$  and, S3:17, 18
- Pancytopenia, severe, diagnostic testing strategies for, 42
- Paroxysmal nocturnal hemoglobinuria, XCIP analysis, 368
- Pathfinder DNA vaccines, for multiple myeloma, S3:38-39
- PCAB chemotherapy, for multiple myeloma, S3:5
- PCR-based techniques  
 for ALL treatment monitoring, 408  
 automated quantitative real-time (RT-PCR), 396-397  
 for  $\beta$ -globin gene detection, 332-334  
 contamination of, 383  
 disadvantages of, 358  
 for Ig/TCR V-(D)-J gene rearrangement detection, 378-379  
 for minimal residual disease detection  
   DNA-based, 382-383  
   RNA-based, 382-383  
 reverse-transcriptase  
   of clonality, 364-365  
   for monitoring of residual disease in AML, 397-398  
   quantitative abnormalities in lymphoid malignancies, 380  
   for viral infection diagnosis, 356-357  
 for  $\alpha$ -thalassemia detection, 330-331  
 for treatment monitoring, 405-406  
 for viral infection diagnosis, 356-357  
 for XCIP analysis, 363-364
- Peripheral blood smears, in folate or cobalamin deficiency, 36-37
- Peripheral neuropathies, folate deficiency and, 54-55
- Peripheral T-cell lymphomas, 168
- Pernicious anemia  
 in blacks, 94-95  
 diagnosis of, 41, 93-94  
 diagnostic testing strategies, 42  
 folate supplementation for, 71-72
- Peyer's patches, 139
- PF4, S1:8
- Plasma cells, in marginal-zone B-cell lymphoma, 132
- Plasmapheresis, for heparin-induced thrombocytopenia, S1:29-31
- Platelet aggregation assay, for HIT/HITTS evaluation, S1:23, 24-28
- Platelet counts, in heparin-induced thrombocytopenia, S1:17
- PLL. *See* Polymorphocytic leukemia
- p53 mutations, in mantle-cell lymphoma, 122
- Polycythemia vera  
 clinical features, S2:10  
 diagnosis, S2:1, S2:9-10  
 differential diagnosis, S2:9-10  
 mortality/morbidity, S2:11-12  
 natural course, S2:10-11

- Polycythemia vera (*Continued*)  
 pathogenetic mechanisms, S2:3-4  
 treatment  
 alkylating agents for, S2:20-21  
 aspirin for, S2:21-22  
 historical perspective, S2:19-22  
 hydroxyurea for, S2:19-20  
 interferon- $\alpha$  for, S2:21
- Polycythemia Vera Study Group (PVSG), S2:9
- Polymerase chain reaction. *See* PCR-based techniques
- Polymorphonuclear leukocytes (PMN), in folate deficiency, 59
- Popcorn cells. *See* Lymphocytic and/or histiocytic cells
- p53 protein overexpression, in mantle-cell lymphoma, 122
- PRAD-1 oncogene, in mantle-cell lymphoma, 121
- Pregnancy  
 essential thrombocythemia in, S2:17  
 folate deficiency during, 54
- Preimplantation diagnosis, 329
- Prenatal diagnosis, advances in, 328-329
- Preneoplastic conditions, folate deficiency and, 58
- Progressively transformed germinal center (PTGC)  
 components, 242  
 lymphocyte-predominant Hodgkin's lymphoma and, 249
- Prolymphocytic leukemia (PLL)  
 differential diagnosis, 109  
 T-cell, 164-165
- Protein chips, 359
- Psychiatric manifestations, of folate deficiency, 43
- PTGC. *See* Progressively transformed germinal center
- Purine analogs, for hairy-cell leukemia, 157-159
- PURA, for mycosis fungoides, 167
- PVSG (Polycythemia Vera Study Group), S2:9
- Racial differences, in cobalamin serum levels, 88, 89-91
- Radiotherapy, for small lymphocytic lymphoma, 205
- Rai and Binet staging system, for B-chronic lymphocytic leukemia, 104, 105
- ras oncogene mutations, in multiple myeloma, S3:11
- R-binder. *See* Transcobalamin I
- RDA (representational difference analysis), 359
- RDB method,  $\beta$ -globin gene detection, 333
- REAL classification  
 Hodgkin's lymphoma, 221-222, 233  
 indolent nonfollicular lymphomas, 198-199  
 small lymphocyte cell disorders, 104, 105  
 T-CLL, 164-165  
 v other classifications, 101, 198, 209
- Recombinant hirudin, for heparin-induced thrombocytopenia, S1:19-20
- Red blood cell disorders. *See also specific red blood cell disorders*  
 nonglobin, genetic diagnosis of, 334-335
- Red blood cell folate levels  
 B<sub>12</sub>/folate status and, 10  
 in oral contraceptive users, 29
- Reed-Sternberg cells (RS)  
 chemokine/chemokine receptor expression, 255-258  
 in classical v NLP Hodgkin's lymphoma, 253  
 expression of costimulation-associated ligands, 254  
 Ig and TCR gene rearrangements, 236-237  
 L&H variant. *See* Lymphocytic and/or histiocytic cells
- Reed-Sternberg cells (RS) (*Continued*)  
 lymphoid cell lineage and, 235-236  
 mapping onto normal B-cell development, 237-239  
 surrounding lymphocytes, phenotype of, 253-254  
 T cells around, cytokine production of, 255  
 TCR gene rearrangements, 236-237  
 v nonlymphoid cells in classical HL, 235
- Representational difference analysis (RDA), 359
- Retinoic acid receptor- $\alpha$ , translocations, in AML, 392-393
- Revised European-American Lymphoma classification (REAL), 101
- Richter's syndrome, 108-109
- RNA analysis, of clonality, 364-365
- RS cells. *See* Reed-Sternberg cells
- RT-PCR. *See* PCR-based techniques, reverse-transcriptase
- Rye Conference classification, of Hodgkin's lymphoma, 221
- S-adenosylhomocysteine (SAH)  
 biosynthesis, 4-5  
 in B<sub>12</sub> neuropathy  
 in HIV-infected patients, 82, 83  
 ratio to SAM, 9-10  
 function, 49  
 in vascular disease, 51
- S-adenosylmethionine (SAM)  
 antidepressant effects, 55-56  
 assay method, 39  
 biosynthesis, 4-5  
 in B<sub>12</sub> neuropathy  
 in HIV-infected patients, 82-83  
 ratio to SAH, 9-10  
 homocysteine elevations and, 48
- Salivary gland MALT lymphoma, 144-145
- SAPK (stress-activated protein kinase), S3:15
- Schilling test  
 food cobalamin malabsorption and, 40-41  
 in HIV-infected patients, 79, 80
- SCID mouse multiple myeloma model, IL-6 regulation of, S3:14-15
- L-Selectin, in B-chronic lymphocytic leukemia, 181, 182-183
- Serotonin release assay (SRA), S1:17-18, 23-28
- Sézary syndrome, 167-168
- Sickle cell disease  
 $\beta$ -globin gene defects, diagnosis of, 331-332  
 incidence, 329  
 mutations, 328
- Skewing, in XCIP interpretation, 365-367
- SLL. *See* Small lymphocytic lymphoma
- SLVL. *See* Splenic lymphoma with villous lymphocytes
- Small lymphocyte disorders. *See also specific small lymphocyte disorders*  
 bone marrow features, 106  
 clinical features, 104-105  
 cytogenetic/molecular features, 108  
 diagnosis, 109  
 disordered immunity in, 107-108  
 genetics, 171-174  
 hematologic features, 105-106  
 immunophenotype, 107  
 lymph node biopsy, 106-107  
 prognosis, 108

- Small lymphocyte disorders. *See also specific small lymphocyte disorders (Continued)*  
 REAL classification, 104, 105
- Small lymphocytic lymphoma (SLL)  
 adhesion molecules in, 181, 186-187  
 bone marrow features, 106  
 classification, 199  
 clinical features, 104-105, 200  
 cytogenetic/molecular features, 108  
 cytogenetics, 174  
 differential diagnosis, 109, 110  
 disease transformation features, 108-109  
 disordered immunity in, 107-108  
 hematologic features, 105-106  
 immunophenotype, 107  
 lymph node biopsy, 106-107  
 malignant monocytic B cells in, 132  
 prognosis, 108  
 treatment, 203-205
- Southern blot analysis, of lymphoid clonality, 377-378
- Spleen  
 histology, in SLVL, 150-151  
 in mantle-cell lymphoma, 118
- Splenectomy  
 for hairy-cell leukemia, 157  
 for splenic lymphoma with villous lymphocytes, 153
- Splenic lymphoma with villous lymphocytes (SLVL)  
 adhesion molecules in, 181, 187-188  
 bone marrow findings, 150  
 clinical features, 148-149  
 cytogenetics, 151-152  
 differential diagnosis of, 109  
 immunophenotype, 149-150  
 laboratory features, 148-149  
 morphology, 148-149  
 natural history, 152-153  
 pathogenesis, 152  
 prognosis, 152-153  
 splenic histology, 150-151  
 treatment, 153
- Splenomegaly  
 hyperreactive malarial, v SLVL, 152  
 in splenic lymphoma with villous lymphocytes, 149
- SRA (serotonin release assay), S1:17-18, 23-28
- Stem-cell donation, viral infections from, 354
- Stem-cell transplantation  
 allogeneic. *See* Allogeneic stem-cell transplantation  
 for multiple myeloma, S3:1, 4-5
- StemSep selection device, S3:24
- Stress-activated protein kinase (SAPK), S3:15
- Subacute combined degeneration of spinal cord (SACD), folate deficiency and, 54, 56
- TAA's. *See* Tumor-associated antigens
- TARC (thymus and activation-related chemokine), in Reed-Sternberg cells, 255-256
- Tartrate-resistant phosphatase activity (TRAP), in hairy-cell leukemia, 156
- T-cell ALL, chromosomal abnormalities in, 381
- T-cell/histiocyte-rich large-B cell lymphoma, 227-228
- T-cell large granular lymphocyte leukemia (T-LGL), 166
- T-cell prolymphocytic leukemia (T-PLL)  
 characteristics, 165  
 small-cell variant, 164-165
- T cells  
 costimulated, usage of, 27-29  
 interactions with RS cells, 255
- TCR gene rearrangements  
 in classical Hodgkin's lymphoma, 235-237  
 PCR detection of, 379  
 TCR $\alpha$ / $\beta$  loci and, 376
- Tetrahydrofolates (THFs), 4-5
- $\alpha$ -Thalassemia  
 clinical implications, 329  
 deletional, diagnosis of, 330-331  
 non-deletional, diagnosis of, 331
- $\beta$ -Thalassemia  
 clinical implications, 329  
 $\beta$ -globin gene defects, diagnosis of, 331
- Thalidomide, for multiple myeloma, S3:12
- THFs (tetrahydrofolates), 4-5
- Thrombin inhibitors  
 cost considerations, S1:51  
 monitoring, S1:50-51  
 neutralization, S1:49-50  
 pharmacologic development, S1:42-46  
 structural characteristics, S1:43-45
- Thrombocytopenia, drug-induced immune. *See* Drug-induced immune thrombocytopenia
- Thrombolytic therapy, with antithrombin agents, S1:48
- Thrombosis, in essential thrombocythemia, S2:14-15
- Thrombosis in Myocardial Infarction trial (TIMI), S1:47, 48
- Thymus and activation-related chemokine (TARC), in Reed-Sternberg cells, 255-256
- TIMI (Thrombosis in Myocardial Infarction trial), S1:47, 48
- T-LGL (T-cell large granular lymphocyte leukemia), 166
- T lymphocytes. *See* T cells
- T-lymphocytes, TAA-specific responses, dendritic cells and, S3:21-22
- TNF (tumor necrosis factor), in Hodgkin's lymphoma, 254
- Topical chemotherapy, for mycosis fungoides, 167
- TPO, in essential thrombocythemia, S2:4
- Transcobalamin I (R-binder)  
 in cobalamin absorption from food, 13  
 deficiency, 24, 96  
 ethnic variations, 92-93, 96  
 in HIV-infected patients, 78
- Transcobalamin II  
 deficiency, 24  
 ethnic variations, 92-93  
 function, 19  
 in HIV-infected patients, 78
- Transforming growth factor- $\beta$ , Hodgkin's lymphoma immune response and, 255
- Translocations  
 acute myeloid leukemia, 392-393  
 acute promyelocytic leukemia, 392-393  
 B-cell chronic lymphocytic leukemia, 172  
 follicular lymphoma, 173-174  
 mantle-cell lymphoma, 119-120, 121, 173  
 splenic lymphoma with villous lymphocytes, 151-152

- Translocations (*Continued*)  
TRAP (tartrate-resistant phosphatase activity), in hairy-cell leukemia, 156  
Trisomy 12  
    in B-CLL, 172  
    in splenic lymphoma with villous lymphocytes, 152  
T-small lymphocyte disorders, 160  
Tumor-associated antigens (TAAs)  
    dendritic cells and, S3:21  
    identification of, S3:22-23  
Tumor burden, indolent nonfollicular lymphomas and, 201-202  
Tumor necrosis factor (TNF), in Hodgkin's lymphoma, 254  
  
VAD chemotherapy, for multiple myeloma, S3:3, 5  
VAMP chemotherapy, for multiple myeloma, S3:5  
Vascular cell adhesion molecule (VCAM), 179  
Vascular disease, folate deficiency and, 15  
Vascular endothelial growth factor (VEGF), S3:11  
Vascularization, in multiple myeloma, S3:12  
Vascular occlusive disease, folate deficiency and, 52-53  
VBAP chemotherapy, for multiple myeloma, S3:5  
VBMCP chemotherapy, for multiple myeloma, S3:5  
VCAM (vascular cell adhesion molecule), 179  
V-(D)-J rearrangement, in B-lymphoid development, 373-375  
VEGF (vascular endothelial growth factor), S3:11  
Venous thrombosis, antithrombin agents for, S1:48  
Very late antigen-4 (VLA-4)  
    characteristics, 179  
    multiple myeloma cell growth and, S3:14  
Very-late antigen-4 (VLA-4)  
    in B-chronic lymphocytic leukemia, 181-184  
Viral infections. *See also specific viruses (Continued)*  
    diagnostic techniques for, 355-356  
    disease pathogenesis and, 352-353  
    as etiologic agents, 353-354  
    hematologic consequences, 353  
    molecular diagnosis, 356-358  
    novel, identification of, 358-359  
    as treatment complications, 354-355  
Viral load, quantitation of, 358  
Vitamin assays, in folate or cobalamin deficiency, 38-39  
Vitamin B<sub>12</sub>-binding proteins, in HIV-infected patients, 78  
Vitamin B<sub>12</sub> deficiency. *See* Cobalamin deficiency  
VLA-4. *See* Very late antigen-4  
VMCP chemotherapy, for multiple myeloma, S3:5  
  
Waldenström's macroglobulinemia  
    bone marrow features, 106  
    clinical features, 105  
    cytogenetics, 174-175  
    differential diagnosis, 109-110  
    disease transformation features, 108-109  
    disordered immunity in, 107-108  
    hematologic features, 105-106  
    immunophenotypic features, 107  
    lymph node biopsy, 106-107  
    prognosis, 108  
WF (Working Formulation), 101, 198, 203  
WHO classification  
    Hodgkin's lymphoma, 221-222, 233  
    indolent nonfollicular lymphomas, 198-199  
    "nodal," use of term, 128  
    v other classifications, 101, 198  
Women, acquired folate deficiency in, 28-29  
Working Formulation (WF), 101, 198, 203  
World Health Organization classification (WHO). *See* WHO classification  
  
X-chromosome inactivation pattern (XCIP)  
    clinical applications, 367-370  
    DNA analysis, 363-364  
    interpretation, 365-367  
    polymorphic loci for analysis, 361-362  
    RNA analysis, 364-365